Swedish Orphan Biovitrum AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Swedish Orphan Biovitrum AB
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
After Jounce, Concentra Pounces On Atea
Concentra's unsolicited bid for Atea is the latest proof that promising but financially strapped biotechs that are trading below cash are prime M&A targets.
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy
Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Akinion Pharmaceuticals AB
- Arexis AB
- Biovitrum AB
- Dova Pharmaceuticals, Inc.
- Sobi, Inc.
- Swedish Orphan International Holding AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.